Overview

A Study for Patients With Multiple Sclerosis

Status:
Terminated
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
To obtain additional safety data in subjects who have previously completed the MBP8298-01 study "A Double Blind Placebo Controlled Multi-Centre to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Multiple Sclerosis" Dirucotide is generic name for MBP8298.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
BioMS Technology Corp.